Literature DB >> 7264792

Elevated IgA concentration in milk produced by mothers delivered of preterm infants.

S J Gross, R H Buckley, S S Wakil, D C McAllister, R J David, R G Faix.   

Abstract

Concentrations of immunoglobulins G, M, and A were measured by double-antibody radioimmunoassay in morning milk samples collected during the first month postpartum from 35 mothers delivered of preterm infants and 14 mothers delivered of term infants. Mean concentrations of IgG (1.8, to 2.8 mg/gm protein) and IgM (2.8 to 11.7 mg/gm protein) were similar in milk from both groups of mothers. In contrast, IgA was present in significantly higher concentrations throughout the first month postpartum in milk from mothers delivered of preterm infants than in milk from those giving birth at term (P less than 0.01). To determine the effect of milk flow on IgA concentration, IgA was also measured in complete 24-hour milk collections; milk from mothers with preterm deliveries again contained significantly higher concentrations of IgA than milk from mothers with term deliveries (P less than 0.01). This higher IgA concentration was not secondary to method of milk expression. The concentration of IgA was found, however, to vary inversely with milk volume (P less than 0.01). Although mean values of milk volumes for the groups were not statistically different, the overall lower volumes of milk produced by mothers giving birth preterm resulted in comparable total IgA production per 24 hours. There were no differences in serum IgA concentrations of preterm infants fed their own mother's milk and comparable infants fed a cow milk formula, suggesting that IgA in milk is not absorbed from the intestine in significant amounts.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7264792     DOI: 10.1016/s0022-3476(81)80323-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Survival of Immunoglobulins from Human Milk to Preterm Infant Gastric Samples at 1, 2, and 3 h Postprandial.

Authors:  Veronique Demers-Mathieu; Mark A Underwood; Robert L Beverly; David C Dallas
Journal:  Neonatology       Date:  2018-06-25       Impact factor: 4.035

2.  Immunoglobulin A concentrations in commercial immune globulins.

Authors:  R Apfelzweig; D Piszkiewicz; J A Hooper
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

3.  Immunoglobulin profile of the preterm baby.

Authors:  S P Conway; P R Dear; I Smith
Journal:  Arch Dis Child       Date:  1985-03       Impact factor: 3.791

4.  Antimicrobial properties of preterm breast milk cells.

Authors:  J F Murphy; M L Neale; N Matthews
Journal:  Arch Dis Child       Date:  1983-03       Impact factor: 3.791

Review 5.  Anti infective properties of breast milk.

Authors:  S Shashikala; J Prakash
Journal:  Indian J Pediatr       Date:  1984 Jul-Aug       Impact factor: 1.967

6.  Isotype, subclass and molecular size of immunoglobulins in salivas from young infants.

Authors:  D J Smith; W F King; M A Taubman
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

Review 7.  Academy of Breastfeeding Medicine founder's lecture 2008: breastfeeding--an extrauterine link between mother and child.

Authors:  Samuli Rautava; W Allan Walker
Journal:  Breastfeed Med       Date:  2009-03       Impact factor: 1.817

8.  Characteristics of breast milk and serology of women donating breast milk to a milk bank.

Authors:  P C Lindemann; I Foshaugen; R Lindemann
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-09       Impact factor: 5.747

Review 9.  Pathogenesis of NEC: Role of the innate and adaptive immune response.

Authors:  Timothy L Denning; Amina M Bhatia; Andrea F Kane; Ravi M Patel; Patricia W Denning
Journal:  Semin Perinatol       Date:  2016-12-09       Impact factor: 3.300

Review 10.  Donor human milk versus formula for preventing necrotising enterocolitis in preterm infants: systematic review.

Authors:  W McGuire; M Y Anthony
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.